The selective ER modulator tamoxifen can antagonize ERα transcriptional activation to control breast cancer progression by competitively inhibiting estrogen binding and is regarded as a primary option for endocrine therapy in ER+ breast cancer [2]. This evidence concerns the gene ESR1 and breast carcinoma.